Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.
You may also be interested in...
Amarin’s Q1 Vascepa Sales Exceed Expectations, But Uncertainties Remain
First quarter revenue of $150m beat analyst consensus of $129m, but investors remain wary of Amarin’s ability to overturn its recent Vascepa patent defeat and execute a favorable European strategy.
Amarin's Vascepa Momentum Builds Ahead Of Next Week's FDA AdComm
Sales of the triglyceride-lowering medicine soared to $112.4m in the third quarter even before a label expansion that depends on the outcome of a vital US FDA advisory committee meeting on 14 November.
Amarin CEO Thero On Gearing Up For Success Ahead Of The Big Vascepa Ad Comm
"We're planning for success," John Thero told Scrip in an interview, where he talked about the upcoming US advisory committee meeting for Vascepa, commercial expansion plans and deflected questions about a big pharma buyout.